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Abstract
This chapter summarizes recent research on the coronary collateral circulation. The chap-
ter is focused on clinical perspectives and importance of a well-developed coronary col-
lateral circulation, the mechanisms of growth induced by chemical factors and a role 
for stem cells in the process. Some discussion is devoted to the role of shear stress and 
mechanical signaling, but because this topic has been reviewed so extensively in the 
recent past, there is only small mention of its role in the growth of the coronary collateral 
circulation.
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1. Introduction
Although arteriogenesis has been studied for approximately a hundred years, there are still 
fundamental unanswered questions about the causes of collateral vessel growth, and whether 
different factors control growth at varying points in the maturation process. One line of inves-
tigation, spurred by the myriad contributions of Schaper and his colleagues have focused on 
mechanical shear stress being the main factor that stimulates collateral growth [1–4]. Although 
this hypothesis is well-founded on a large body of experimental data, it does not explain 
other observations that show collateral growth in the absence of altered shear stress [5, 6]. 
Accordingly investigators have proposed that ischemia (via cytokine, chemokine, and growth 
factor expression), and the consequential inflammation, is the cause of collateral growth, but 
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assessing it has proven to be difficult due to the unclear lines between ischemic regions, nor-
mal circulation, and collateral growth. The hypotheses regarding the causative factor(s) for 
collateral growth are not mutually exclusive as there are likely many mechanisms that are 
the principal driver, which vary at various points of the process. For example, even if one 
maintains that ischemia is the initiating mechanism for collateral growth, it is likely that other 
stimuli continue the growth of the vessel after the ischemic stimulus has waned. To provide 
perspective for this chapter, we refer to Figure 1, which summarizes four factors that exert 
important effects in this adaptive process. The bulk of this chapter will focus on the collateral 
growth from a clinical perspective, the role of stem cells, and chemical factors involved in this 
process. We will not extensively review the role that shear stress in coronary collateral growth 
as this has been reviewed ample times in the past. We also will not review the genetic aspects 
because the bulk of this information has been derived from studies of collateral growth in 
vascular beds other than the heart, e.g., skeletal muscle and brain [7, 8], although there is some 
preliminary information about genetic links to collateral growth in patients [9]. Figure 1 also 
shows the anatomical structure of a collateral; namely, an arterial-arterial anastomosis that 
connect large coronary perfusion territories. Collateral growth, also known as arteriogenesis, 
in the heart involves the abluminal expansion of a preexisting arterial-arterial anastomosis 
[10]. The degree of expansion is profound—the caliber of collateral vessels can increase over 
an order of magnitude [10]. This degree of expansion would greatly reduce vascular resistance 
of these vessels, thereby increasing flow in the area of risk. This increase in flow is the reason 
why the collateral circulation exerts beneficial effects through the reduction in infarct size (fol-
lowing a coronary occlusive event) and reduction in the incidence of sudden cardiac death.
We also would like to point out an obvious distinction between the growth of collateral ves-
sels (arteriogenesis) and angiogenesis. These processes are often confused as the same, but 
 Figure 1. An image of the human coronary circulation depicting large collateral vessels that connect perfusion territories 
of major arteries and some factors that regulate their development.
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they are distinct and have distinguishing characteristics. In A Brief Etymology of the Collateral 
Circulation, Faber et al. describe angiogenesis as the formation of capillaries from preexisting 
capillaries [11]. In contrast to angiogenesis, arteriogenesis is more the remodeling of preexist-
ing vessels through the “anatomic increase in lumen area and wall thickness.” The causes of 
arteriogenesis are more physical, specially, mechanical shear stress and ischemic conditions, 
while angiogenesis is caused by chemical conditions such as hypoxia [11].
2. Clinical perspective
Heart disease is extremely prevalent in the United States, where it accounts for every one in 
four deaths and almost 735,000 Americans suffer a heart attack each year (Centers for Disease 
Control, USA). However, there are numerous differences between these individuals in terms 
of response to treatment, future adverse events, and long-term survival rates. One explana-
tion for these differences involves the presence of good collateral growth in certain individu-
als. A 5-year study called Osaka Acute Coronary Insufficiency Study (OACIS) assessed both 
acute and long-term survival in patients and came to three important conclusions: (1) patients 
with a Rentrop collateral score (RCS) of one or two showed the most promising 5-year sur-
vival rates, (2) RCS of three was associated with a worse 5-year survival rate, (3) RCS of three 
was associated with the best survival rates in a specific subgroup of patients with single vessel 
disease without previous myocardial infarction (MI) [12]. These first two conclusions can be 
explained due to the fact a higher baseline RCS can be indicative of a worse background of 
clinical characteristics such as previous MI or angina pectoris resulting in increased mortality 
rates, whereas an RCS of one or two was developed in the acute setting negating any adverse 
effects of chronic ischemia [12]. The third conclusion states RCS of three is more beneficial 
in the setting of single vessel occlusion and without previous MI, which would liken it to 
individuals who have RCS of one or two, but without any previous adverse events. In this 
subgroup, patients are having increased collateral flow, but without the chronic angina pec-
toris or previous MI improving survival rates [12]. This information leads to an important 
conclusion where the increased number of collaterals does not equate to decreased mortality 
rates, but rather is dependent upon a multitude of factors.
2.1. Methods
The literature is replete with the salubrious effects of a well-developed coronary collateral 
circulation and the potential benefit of a therapeutic process aimed at stimulating coronary 
collateral growth [13–19]. One patient study focused on coronary collateral growth in patients 
that had stable coronary artery disease. Specifically, the Möbius-Winkler et al. study looked at 
the impact of exercise on coronary collateral growth [20]. The patients were put into groups 
of usual care, moderate intensity exercise, and high-intensity exercise. The main findings of 
this study were that moderate and high-intensity exercise increased the coronary collateral 
blood flow. Scientists in this study postulated the cause of the coronary collateral growth. 
They questioned whether ischemia triggers collateral growth, since a percutaneous coronary 
intervention was performed before the study began; however, there is a large body of litera-
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ture suggesting the PCI procedures may not completely resolve myocardial ischemia. The 
authors further speculated that the cause could be this increased blood flow and could have 
been from either increasing work done by preexisting blood vessels or an “improvement in 
endothelial function of small intramyocardial vessels.” There was a CFI increase of 39% in the 
group of patients that did high-intensity exercise and a 41% CFI increase in the group that did 
moderate intensity exercise, which emphasized that exercise increased the coronary collateral 
blood flow in patients with coronary artery disease [20].
There has been much discussion for stimulating arteriogenesis in patients in order to give them 
proper blood perfusion to ischemic areas. Collaterals have been found to give patients many 
benefits over individuals who do not have collaterals, with a long-term mortality reduction, 
reduced myocardial infarct size, a greater postinfarction ejection fraction, and a reduced risk 
for rupture of the papillary muscle, myocardial free wall, or interventricular septum [21]. A 
reduction in infarct size was noted by the decreased peak creatinine levels as the number of 
collaterals increased depicting a cardioprotective effect [12]. Additionally, specific benefits 
have been noted between the presence of collaterals and sudden cardiac death and myocardial 
infarction.
There are three prevalent assessment methods of collateral growth circulation: the Rentrop 
score, collateral flow index (CFI), and intracoronary electrocardiogram. The Rentrop score 
can be most easily assessed when using coronary angiography as a visual assessment method. 
Circulation is then categorized into four different grades: Grade 0, Grade 1, Grade 2, and 
Grade 3. These categories range from no filling of the coronary collaterals to complete filling 
of collaterals, respectively. Although successful, the Rentrop method has some limitations 
due to being easily influenced by blood pressure changes and the force of injections during 
imaging procedures. Currently, the method considered to be the most accurate is the collat-
eral flow index measurement. This method centers around utilizing a Doppler sensor tipped 
guide wire to quantify flow velocity in an occluded vessel compared with a normal vessel. 
Briefly mentioned was the intracoronary electrocardiogram, which is regarded as “simpler, 
cheaper, and very accurate” [22].
2.2. Benefits of coronary collaterals
Although many in the preclinical models have been employed in the study of coronary col-
lateral growth, there is a relative paucity of clinical studies that have attempted to elucidate 
mechanisms of growth. One of the first studies done was in 1971 and was published in the 
New England Journal of Medicine [23]. This study only had three successful trials that demon-
strated collaterals alleviating cardiovascular mortality. The inconsistency, according to Meier 
et al., could be rooted in the method by which they measured coronary collateral growth. 
The 1971 study “qualified” collaterals visually using coronary angiography, but Meier et al. 
postulates that had a better measurement method such as CFI been used, results could have 
been more promising [22].
One successful clinical study was performed by Seiler et al., which found that there is a direct 
correlation between collateral function and atherosclerotic lesions [24]. Patients with chronic 
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total coronary occlusions had higher CFI values than those patients who did not have this 
condition. A CFI shift was quantified that patients with coronary occlusions had a CFI of 0.365 
± 0.190 versus 0.180 ± 0.105 of that of patients without occlusions. This study directly demon-
strated that “collateral function is a direct indicator of CAD severity.” The clinical importance 
of these findings suggests that human coronary collaterals can act as a “marker of poor out-
come” in diseases such as acute coronary syndromes.
Sudden cardiac death (SCD) has several causes including electrical instability of the heart, spe-
cifically QRS complex variabilities can be used as markers for SCD and at times even trigger SCD 
[25]. The Oregon Sudden Unexpected Death Study (Ore-SUDS) has shown that prolongation of 
the QRS complex is associated with a large increase of SCD due to both known and unknown 
causes; therefore, methods to reduce this adverse event in the presence of myocardial ischemia 
can reduce mortality [26]. Additionally, fragmented QRS (fQRS), which are various RSR pat-
terns in two continuous leads, have a well-established relationship with cardiac fibrosis caused 
by previous myocardial infarction or ischemia [27]. fQRS patterns have also been associated with 
increased morbidity and mortality, SCD, and repeat cardiovascular (CV) events and were found 
more often in individuals with poor collateral growth [27]. The presence of a well-developed 
collateral network has been shown to reduce QRS prolongation in left coronary artery occlusion 
and occurrence of fQRS in patients with chronic total occlusion [25, 27]. With this information, it 
can be concluded that with an increased number of coronary collaterals, patients can avoid QRS 
complex abnormalities thereby decreasing the chances of sudden cardiac death.
Additionally, the presence of collaterals has shown an increased time from symptom-onset-
to-perfusion (>6 hours in good collateral versus poor collateral). This enables patients to 
increase the amount of time before onset of detrimental cardiac damage [28]. During an acute 
MI, the presence of a well-developed collateral circulation was seen in infarcted tissue that 
did not undergo cell necrosis, proving that increased collaterals will increase the chances of 
myocardial viability [29–31].
Overall, the presence of a well-developed collateral circulation in conjunction with healthy base-
line characteristics (absence of repeat MI or angina pectoris) will be protective in patients who 
may suffer SCD, MI, or bouts of ischemia. Working to induce this collateral growth in patients 
both mechanically and chemically will prove to be very beneficial in decreasing mortality rates 
of patients with heart disease and perhaps ameliorate the possibility of recurrent cardiac events.
3. Mechanical factors involved in coronary collateral growth
The precise stimulation of arteriogenesis is yet to be found; however, both mechanical and 
chemical influences are required to induce the formation of collaterals in the heart. Mechanical 
shear stress occurs due to increased pressure gradients that form when an occlusion is pres-
ent [32]. A stenotic artery will increase the pressure prior to the occlusion while decreasing 
the pressure distal to the occlusion. The increased pressure above the occlusion will cause an 
increase in blood flow into capillary beds prior to the occlusion increasing the shear stress 
[32]. The increased movement of blood into pre-existing collaterals and the resultant increased 
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shear stress leads to several changes in the capillary endothelium. The first of which includes 
an increase in MCP-1 that serves to attract more monocytes to the proliferative site in order 
to transform them into the subsequent macrophages. The macrophages play a vital role in 
releasing cytokines and growth factors required for arteriogenesis. TNF-α, released by macro-
phages, helps form the inflammatory environment required for the growth of collaterals [33]. 
Another major factor includes basic fibroblast growth factor (bFGF), which helps with the 
actual development of collaterals [32]. A more in depth analysis on chemical inducers will be 
discussed later on in this chapter.
Although mechanical shear stress is thought to be a major contributor to arteriogenesis, it 
cannot be the sole solution due to the inability of fluid shear stress to completely replace 
the conducting artery. Fluid shear stress (FSS) has been found to only reach 35–40% of the 
maximal conductance possessed by the original stenotic artery [34]. An explanation for this 
phenomenon can be found in the relationships: FSS and blood flow velocity and FSS and cube 
of the vessel radius. FSS and blood flow velocity have a proportional relationship, while FSS is 
inversely related to the cube of the vessel radius [34]. The increase in blood flow velocity in the 
pre-existing collaterals leads to an increase in FSS. Since the shear stress causes growth in the 
collaterals (meaning an increase in the vessel radius), the FSS begins to decline preventing full 
recovery of the stenotic artery [34]. This indicates the need for both mechanical and chemical 
effectors for the production of proper coronary collaterals.
4. Chemical factors involved in coronary collateral growth
In addition to mechanical mechanisms of arteriogenesis, there are several chemical mediators 
involved in regulation of the process. Many of these chemical factors modulate the functions 
of the various cell types involved in arteriogenesis, including induction of cell proliferation, 
chemotaxis, and cellular remodeling. In this section, we will outline the various chemical 
mediators that are currently known to play a role in arteriogenesis.
4.1. Vascular endothelial growth factor (VEGF)
Vascular endothelial growth factor (VEGF) is known to play a major role in development of 
new vasculature. Under hypoxic conditions, VEGF production and release stimulates new 
capillary formation (angiogenesis) via endothelial cell sprouting, proliferation, and migration 
[35]. Alternatively, under different conditions, it can instead stimulate growth of new arter-
ies, formation of collateral vessels, and modulation of lumen expansion—these actions are 
collectively referred to as arteriogenesis [35].
In VEGF signaling, there are three primary cell-surface receptors to which it binds: two 
tyrosine kinase receptors VEGFR-1 and VEGFR-2 and a nonkinase receptor neuropilin-1 
(NRP-1) [35–37]. There are multiple isoforms of VEGF, with VEGF-A playing the major role in 
endothelial cell function via binding to VEGFR-2 [35]. VEGFR-2 is also involved in signaling 
pathways that lead to arteriogenesis via stimulation of proliferation, migration, survival, and 
lumenization of endothelial cells [35].
Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy138
The first of these signaling cascades is activation of phosphatidylinositol 3-kinase (PI3K)/Akt 
that inhibits apoptosis in endothelial cells thus promoting cell survival [35]. The cascade is 
initiated by binding of VEGF-A to VEGFR-2 (Flk-1), which initiates receptor internalization 
via clathrin-coated pits followed by receptor autophosphorylation [35]. Active VEGFR-2 then 
phosphorylates PI3K, which goes on to phosphorylate the serine/threonine kinase Akt, which 
will go on to phosphorylate targets to inhibit apoptosis [38].
The second signal cascade is phosphorylation of profilin-1, indirectly via Src/FAK as well 
as directly via VEGFR-2, which stimulates migration of endothelial cells [35, 37]. Like the 
previous mechanism, this cascade is initiated by binding of VEGF-A to VEGFR-2. Activated 
VEGFR-2 then goes on to phosphorylate profilin-1 as well as Src kinase, which also phos-
phorylates profilin-1 [37]. Phosphorylated profilin-1 then goes on to catalyze the exchange 
of ADP for ATP on G-actin that stimulates polymerization of actin and resultant remodeling 
of the endothelial cell cytoskeleton [37]. This remodeling results in formation of actin-rich 
filopodia extending in the direction of the concentration gradient of VEGF, thus stimulating 
endothelial cell migration [37].
The third signal cascade is activation of the Raf-MEK-ERK signal cascade, which stimulates 
proliferation of endothelial cells, network formation, and increase in lumen size via phos-
phorylation of ERK1/2 [35]. While the exact mechanism of ERK1/2 action on cell proliferation 
and motility is not yet well understood, it has been suggested that a major component of this 
signaling cascade is downregulation of Rho-Kinase activity [39].
Finally, it is important to note that VEGF has been shown to be a critical factor in the process of 
coronary collateral growth. In a study of collateral growth following myocardial infarction in 
rats, it was observed that when the endogenous functions of VEGF were blocked by anti-VEGF 
neutralizing antibody, the result was a complete lack of collateral growth and subsequently 
no increase in coronary flow in the anti-VEGF group [40]. Additionally, upon treatment with 
dipyridamole (a potent vasodilator), it was observed that the increased coronary flow seen in 
the control group was in fact due to collateral growth, as there was no observed increase in 
coronary flow in the anti-VEGF group after the dipyridamole [40]. This study solidifies the 
importance of VEGF in the process of angiogenesis, particularly as it relates to coronary col-
lateral growth.
4.2. bFGF and PDGF
In addition to VEGF, other growth factors are known to play a role in arteriogenesis—notably 
basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) [41]. Basic 
FGF and PDGF are known to induce mitosis in both endothelial and smooth muscle cells 
and also exert other mitogenic effects such as promoting cell migration and differentiation 
[41, 42]. Basic FGF stimulates these mitogenic effects via binding to FGF receptors (FGFRs) 
expressed on cell surfaces [43]. These FGFRs are a part of the tyrosine kinase receptor family, 
and following binding of bFGF dimerize are autophosphorylated to become activated [43]. 
Activated FGFRs, notably FGFR-2 (FGFR-1 is thought to be a regulator of bFGF concentra-
tion available to bind FGFR-2), then continue the signal cascade by activation of cytoplasmic 
mitogen-activated protein kinase (MAPK), which then is translocated to the nucleus to initiate 
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transcription promoting the aforementioned mitogenic effects [43]. PDGF, on the other hand, 
is known to activate multiple other downstream targets including PI3K, phospholipase C 
(PLC), as well as MAPK to mediate its mitogenic effects [44].
4.3. MCP-1 and macrophages
In addition to endothelial cells, macrophages are also heavily involved in arteriogenesis, but 
in order to do so must be directed to the correct location [36]. The primary molecule that 
has been studied as part of this mechanism is monocyte chemotactic protein 1 (MCP-1) [36]. 
Secretion of MCP-1 is initiated by activation of endothelial cell MAP-kinase-protein-kinase-2 
(MK2) by elevation of fluid shear stress [45]. Released MCP-1 subsequently activates mono-
cyte MK2, initiating migration to the correct location [45]. In the last step of the cycle, release of 
inflammatory cytokines by recruited monocytes cause increased secretion of MCP-1 from the 
endothelium, resulting in further monocyte recruitment [45]. Of similarly significant impor-
tance to MCP-1 are two adhesive molecules, intracellular adhesion molecule-1 (ICAM-1), and 
vascular cell adhesion molecule-1 (VCAM-1), which serve to bind the surface of migrating 
monocytes allowing them to roll along the luminal surface of the vasculature [36].
Once the macrophages have reached their destination, the correct phenotype must be expressed 
to stimulate new vessel growth [36]. There are two primary phenotypes of monocyte macro-
phages: M1 macrophages that secrete inflammatory molecules and help fight pathogens and M2 
macrophages that play a role in vascular growth and wound healing [36]. These two phenotypes 
are induced by different cytokines, with interferon-γ causing a shift toward the M1 phenotype, 
while IL-4, IL-13, and several other factors such as IL-10 and IL-33 causing M2 differentiation. 
In histological analysis of hypoxia-induced arteriogenesis, the number of M2 macrophages was 
shown to increase indicating their essential role in development of new vasculature [36].
4.4. NO and eNOS
Nitric oxide (NO) is a potent vasodilator that is produced via the activity of endothelial nitric 
oxide synthase (eNOS). eNOS has been shown to function in stimulating production of new 
vasculature, and its expression is also known to be upregulated in response to elevated fluid 
shear stresses—a principal mechanical stimulus of arteriogenesis [46]. While the exact effects 
of NO and eNOS on arteriogenesis are still controversial, it has been shown that one contribu-
tion of elevated NO due to increased expression of eNOS is a reduction of vascular endothelial 
cadherin (VE-cadherin), resulting in increased vascular permeability and indirect promotion of 
macrophage invasion [46]. Additionally, eNOS activity and pharmacological inhibition of eNOS 
were shown to play a role in mediating vascular remodeling during collateral growth [47, 48].
4.5. Catestatin
Catestatin is a neuroendocrine peptide derived from a specific cleavage of the larger pro-
tein human chromogranin A (CgA) [49]. It functions in many different processes within the 
body including secretion of histamine from mast cells, defense against microbes, vasodila-
tion, and attraction of monocytes. It has also been observed that catestatin acts in a pro-
angiogenic capacity, involved in inducing proliferation and migration of endothelial cells 
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as well as formation of capillary tubes [49, 50]. This is accomplished through stimulating 
release of bFGF, which in turn will activate MAPK via binding to FGFR-1 as previously 
discussed [49, 50]. It has also been shown that catestatin activates other signal cascades such 
as PI3K/Akt, serving an anti-apoptotic role to promote cell survival [50]. Finally, catestatin 
influences effects in both endothelial progenitor cells (EPCs) and vascular smooth muscle 
cells (VSMCs) in addition to its direct effects on endothelial cells, inducing chemotaxis to 
incorporate these cell types into formation of new vasculature [50].
4.6. Neuregulins
Neuregulins (NRG) are another class of molecules produced by endothelial cells. These 
growth factor ligands bind to erbB receptors expressed on the surface of endothelial cells—
this action has been shown to induce angiogenesis [51]. NRG involvement in angiogenesis 
and arteriogenesis is tied to regulation of α
v
β
3
 integrin, thus playing a role in cell migra-
tion, proliferation, and differentiation mechanisms as shown in a NRG-erbB knockout mouse 
model. The mechanism by which this occurs involves another proangiogenic protein, Cyr61, 
the expression of which is upregulated by NRG-erbB signaling, in addition to mediation via 
induction of VEGF release and subsequent activation of the ERK signaling cascade [51]. ErbB 
receptors have also been found to be expressed on EPCs, playing a role in increasing cell 
survival, and on certain types of VSMCs, though the role NRG-erbB signaling plays here is 
not well known [51].
4.7. Early growth response 1 (Egr-1)
Early growth response 1 (Egr-1) is a transcription factor of the zinc-finger family that has been 
shown to be upregulated during arteriogenesis [52]. It plays a major role in modulating the 
levels of other growth factors that are involved in the process of collateral growth, including 
playing a role in the recruitment and proliferation of leukocytes [52, 53]. Specific genes that are 
upregulated by Egr-1 include PDGF and transforming growth factor β (TGF-β), which then 
indirectly upregulates other factors involved in collateral growth such as VEGF and metallo-
proteinases [53]. Interestingly, despite the fact that most of these factors have been primarily 
shown to affect angiogenesis, it has been observed that Egr-1 primarily affects the growth of 
arterioles rather than capillaries, indicating its primary role in regulation of arteriogenesis [53].
Much like the other factors mentioned here, Egr-1 production is stimulated primarily by eleva-
tions in fluid shear stress, in this case by activating the Egr-1 gene promoter [54]. It has been 
suggested that this is mediated by the Ras-MEK-ERK1/2 signal cascade in which shear stress 
leads to activation of MEK1, which proceeds to activate ERK1/2 of the MAPK family, and finally 
ERK1/2 activate the protein Elk-1 that induces transcription of Egr-1 [54]. Interestingly, this 
pathway can be activated by very low levels of shear stress due to the sensitivity of ERK1/2 [54].
There are many varying chemical mediators of arteriogenesis, many of which share similar 
signaling pathways leading to their involvement. While some of these mediators have been 
studied extensively and are relatively well understood, there are others whose mechanisms 
have not yet been elucidated and require more investigation. There are likely even more 
chemical mediators involved that have not yet been studied. Going forward, more research 
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will be extremely valuable in understanding the overall chemical mechanism behind collat-
eral vessel growth and how to apply this knowledge to a clinical setting.
5. Role of Stem Cells in Coronary Collateral Growth
In addition to the aforementioned chemical mediators that mitigate the consequences of 
vascular occlusive diseases by stimulating collateral growth, in recent years, stem cell-based 
therapy has been implicated as a possible avenue for vascular regeneration. Stem cells have 
the unique potential of developing into many different cell types in the body. Under certain 
physiologic and experimental conditions, they can be manipulated to grow into specific tissues 
and organ cells with exclusive functionality. This revolutionary discovery for stem cells has 
demonstrated a clinical potential to create new networks of blood-perfused vessels and treat 
human patients with cardiovascular and vascular diseases [55]. The current theory is that stem 
cells may release a series of angiogenic factors, such as VEGF and bFGF, which mobilize vascu-
lar endothelial cells through a paracrine effect [56]. In this section, we will summarize the cur-
rent state of regenerative approaches using stem cells to stimulate coronary collateral growth.
A 2012 study programmed endothelial cells to develop into induced vascular progenitor cells 
(iVPCs) and assessed their ability to induce coronary collateral growth in a rat model in efforts 
to increase blood flow to the collateral-dependent region of risk [57]. iVPCs are also known to be 
less tumorigenic compared with induced pluripotent cells (iPSCs) and are more likely to commit 
to a line of vascular differentiation (they will not turn into cardiomyocytes) [57]. When the iVPCs 
were transplanted into myocardium, they formed blood vessels and improved blood flow mark-
edly better than did natural endothelial cells, mesenchymal stem cells, or iPSCs [57]. However, 
while results showed that partial programming of the endothelial cells was promising enough 
to sprout new blood vessels in the myocardium, one big challenge persists: how to maintain the 
partial programmed state of the cells until they get to their intended destination [57].
In addition, current literature posits that bone marrow-derived stem cells and endothelial 
progenitor cells in arteriogenesis do not physically deposit onto the walls of newly generated 
arteries but rather play the role of supporting cells [58]. The therapeutic induction of collateral 
growth from already established arteries improves any blood flow deficiencies caused by 
blockage in major arteries. Transplanted bone marrow-derived cells act as “cytokine factors” 
and secrete specific growth factors that mediate their effects through paracrine activity [59]. 
As Dr. Matthias Heil of the Netherlands puts it, “bone marrow stem cells provide the software 
and not the hardware in vascular growth” [59]. His group’s study on the hindlimb ischemic 
model with mice revealed that GFP-tagged bone marrow was not localized to endothelial and 
smooth cell markers, but around burgeoning collaterals that were secreting chemokines and 
growth factors [59]. Hence, therapeutic arteriogenesis functions to boost the body’s natural 
angiogenic ability by stimulating the release of pro-angiogenic factors rather than actually 
providing the buildings block for a new artery. A caveat to this is if the processes in the heart 
are different from those in the peripheral circulation.
While there is a continued debate on whether bone marrow-derived multipotent stromal cells 
(MSCs) exert their effect via transdifferentiation or through paracrine activity, there is unequivocal 
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evidence showing that MSCs must first travel to ischemic tissue to achieve a therapeutic benefit 
[60]. MSCs localize to injured tissues by adhering to endothelial cells and migrating across the cell 
wall. Homing of MSCs to injured tissues is optimized by an expression of ligands on endothelial 
cells [60]. A 2009 study showed the importance of epidermal growth factor (EGF) and heparin-
binding epidermal growth factor-like growth factor (HB-EGF) in inducing increased expression of 
these ligands [60]. Specifically, phosphorylation of the EGF-R leads to higher expression of ligands, 
VCAM-1, and ICAM-1 that enhanced MSC adherence and ultimately stimulated coronary collat-
eral growth in rats that had undergone repetitive instances of myocardial ischemia [60]. Coronary 
collateral growth was assessed with the ratio of collateral dependent flow (CZ) to normal zone 
flow (NZ). Exposure of both MSCs and coronary endothelial cells (CECs) to a 100 ng/mL dose of 
EGF for 16 hours maximally increased expression of adhesion molecules compared with samples 
untreated with EGF [60]. The CZ/NZ ratio increased in rats whose MSCs were treated with EGF 
and showed improved cardiac function and decreased left ventricular remodeling compared to 
rats without EGF treatment of MSCs [60].
Another 2009 study involving a rat model of repetitive myocardial ischemia showed that 
granulocyte-colony stimulating factor (G-CSF), a glycoprotein responsible for hematopoietic 
cell proliferation and differentiation of neutrophil granulocytes, also stimulates coronary col-
lateral growth [61]. G-CSF mounts a series of defenses against infectious agents, one of which 
is promotion of neutrophils to release reactive oxygen species (ROS) [61]. This generation of 
ROS was studied both in vivo and in vitro and was shown to directly act on injured cardio-
myocytes. Cardiomyocytes under the influence of G-CSF-induced ROS generate angiogenic 
factors that lead to vascular growth and tube formation in levels comparative to cardiomyo-
cytes induced by VEGF [61]. To the surprise of researchers, this study also demonstrated that 
G-CSF can promote coronary collateral growth without the impetus of repetitive ischemia 
and hence this cytokine can act as a surrogate for ischemia [61].
Majority of the recent clinical trials in humans purport that stem cell-based therapy adequately 
facilitates angiogenesis in patients suffering from peripheral arterial disease and promotes 
wound healing [55]. Specifically, bone marrow-derived stem cell transplantation has shown 
to improve ischemic symptoms, such as claudication, ischemic rest pain, and has augmented 
wound healing in ulcer-related conditions [55]. Nonetheless, these studies have been limited 
by a lack of care standardization, absence of a control group, small sample sizes, dissimilar 
inclusion criteria, and inconsistencies in methods of outcome assessment [55]. In other cases, 
the absence of follow-up procedures has prevented elucidation of long-term effects of treat-
ing peripheral artery disease with stem cells [55]. While the central issues of public safety and 
treatment efficacy linger over the field, progress, albeit limited, has been made in the arena of 
coronary collateral growth.
6. Summary
The process of coronary collateral growth is being better understood year by year. The role 
that the many chemical factors, mechanical factors, and stem cells play in the process is still 
incompletely understood. The study of these factors in “normal” preclinical models may be 
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an oversimplification, because under conditions with risk factors for coronary disease, there 
may be shifts in the normal control mechanisms. We advocate that future studies incorpo-
rate models of cardiovascular disease and aging to better understand the mechanisms by 
which this adaptive process is abrogated in the majority of patients with ischemic heart 
disease.
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